FRESENIUS SE+CO.KGAA/ DE0005785604 /
2024-04-26 9:05:23 AM | Chg. -0.28 | Volume | Bid2:42:36 PM | Ask2:42:36 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
26.96EUR | -1.03% | 0 Turnover: - |
26.91Bid Size: 349 | 27.45Ask Size: 820 | 15.24 bill.EUR | - | - |
GlobeNewswire
04-23
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
2023-09-04
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
2023-08-31
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
2022-02-25
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
2022-01-05
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
2021-12-31
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
2021-12-09
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
2021-11-12
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights
GlobeNewswire
2021-10-27
CIO Leadership: Exemplifying Authentic Leadership and Leveraging Personal Branding to Act as a Globa...